Tag: capital markets

SHENZHEN, China, June 25, 2025 (GLOBE NEWSWIRE) -- Fangdd Network Group Ltd. (NASDAQ: DUO) (“DUO” or the “Company”), today announced that on June 24, 2025, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).

In accordance with section 30 of the Capital Markets Act, Pandora A/S hereby announces that
BlackRock, Inc. has notified the company that it now holds 7,485,780 shares, corresponding to 9.47% of the total voting rights and share capital (previously 9.51%). Additionally, BlackRock, Inc. controls voting rights attached to financial instruments amounting to 0.50% (previously 0.49%). In total, BlackRock, Inc. control 9.98% of the company’s voting rights (previously 10.01%).

Company Announcement No 53/2025

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara.

Order represents the first deployment of Actelis' advanced GigaLine solutions with major US telecom carrier, demonstrating growing market recognition of the Company’s innovative ultra-low-power hybrid-fiber technology in the MDU market; Order lays the ground for potential significant expansion and followon orders

Fueled by a 198% surge in Q4 device sales revenue and a 200% increase in shipments, Hapbee’s revitalized marketing strategy, expanded retail footprint, luxury spa partnerships, and high-profile Board additions have set the stage for accelerated growth heading into 2025.

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.